[ES] Cisplatino y carboplatino son dos fármacos muy usados en el tratamiento de tumores
sólidos. Sin embargo, su eficacia está limitada por su nefrotoxicidad. Se ha demostrado que …

Cisplatin and carboplatin are very used drugs for the treatment of solid tumours. However,
their efficacy is limited by their nephrotoxicity. It is known that 25-30% of the patients that …

Despite recent progress in the development of novel approaches to treat cancer, traditional
antineoplastic drugs, such as cisplatin, remain a mainstay of regimens targeting solid …

Background Renal toxicity induced by cisplatin (CisPt) is a clinical issue in patients with or
without chronic kidney disease (CKD). Proximal tubular injury can result in acute kidney …

Nephrotoxicity limits the use of cisplatin (CP) in cancer therapy; however, current clinical
measures of renal health do not reflect low degrees of kidney injury. Therefore, discovering …

Resumen os inhibidores del punto de control inmunitario (IPCI) son un grupo farmacológico
destacable dentro de la inmunoterapia oncológica. Los IPCI se administran en monoterapia …

Background/Aim: We investigated whether measuring the excretion of each acute kidney
injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and …

In recent years, there has been considerable activity to identify urinary biomarkers of
nephrotoxicity as noninvasive measurements with greater sensitivity and specificity than …

Purpose The ability to predict and detect clinical and subclinical nephrotoxicity early in the
course of therapy has the potential to improve long-term outcomes in cancer patients …

Severe adverse systemic drug events occur commonly as a result of treatment of cancer
patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication …